ES2184844T3 - Procedimiento mejorado de sintesis de n-(3-(3-cianopirazolo(1,5-a)pirimidin-7-il)fenil)n-etilacetasmida. - Google Patents

Procedimiento mejorado de sintesis de n-(3-(3-cianopirazolo(1,5-a)pirimidin-7-il)fenil)n-etilacetasmida.

Info

Publication number
ES2184844T3
ES2184844T3 ES96308630T ES96308630T ES2184844T3 ES 2184844 T3 ES2184844 T3 ES 2184844T3 ES 96308630 T ES96308630 T ES 96308630T ES 96308630 T ES96308630 T ES 96308630T ES 2184844 T3 ES2184844 T3 ES 2184844T3
Authority
ES
Spain
Prior art keywords
phenyl
ethylacetasmide
cyanopirazol
pyrimidin
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96308630T
Other languages
English (en)
Inventor
Padmanathan Thurairajah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ES2184844T3 publication Critical patent/ES2184844T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

LA PRESENTE INVENCION ES UNA MEJORA EN LA PRODUCCION DE N-[3(3-CIANOPIRAZOL[1,5-A]PIRIMIDIN-7-IL)FENIL]-N-ETIL-ACETAMIDA, QUE ES UTIL COMO ANSIOLITICO, ANTIEPILEPTICO, AGENTE SEDANTEHIPNOTICO, Y RELAJANTE DEL MUSCULO ESQUELETICO. DICHA MEJORA CONSISTE EN HACER REACCIONAR 3-DIMETIL-AMINO-1-(3-N-ETIL-NACETILAMINOFENIL)-2-PROPEN-1-ONA, O UNA SAL ADECUADA DEL MISMO, CON 3-AMINOPIRAZOL-4-CARBONITRILO, O UNA SAL ADECUADA DEL MISMO, EN UNA MEZCLA QUE COMPRENDE AGUA Y ACIDO ACETICO.
ES96308630T 1995-12-01 1996-11-28 Procedimiento mejorado de sintesis de n-(3-(3-cianopirazolo(1,5-a)pirimidin-7-il)fenil)n-etilacetasmida. Expired - Lifetime ES2184844T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US785995P 1995-12-01 1995-12-01

Publications (1)

Publication Number Publication Date
ES2184844T3 true ES2184844T3 (es) 2003-04-16

Family

ID=21728482

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96308630T Expired - Lifetime ES2184844T3 (es) 1995-12-01 1996-11-28 Procedimiento mejorado de sintesis de n-(3-(3-cianopirazolo(1,5-a)pirimidin-7-il)fenil)n-etilacetasmida.

Country Status (25)

Country Link
US (1) US5714607A (es)
EP (1) EP0776898B1 (es)
JP (1) JP4112032B2 (es)
KR (1) KR100439282B1 (es)
CN (1) CN1057525C (es)
AR (1) AR004822A1 (es)
AT (1) ATE227290T1 (es)
AU (1) AU718310B2 (es)
BR (1) BR9605760A (es)
CA (1) CA2191647C (es)
CY (1) CY2440B1 (es)
CZ (1) CZ292253B6 (es)
DE (1) DE69624657T2 (es)
DK (1) DK0776898T3 (es)
ES (1) ES2184844T3 (es)
HU (1) HU226398B1 (es)
IL (1) IL119710A (es)
MX (1) MX9605974A (es)
NO (1) NO307181B1 (es)
NZ (1) NZ299848A (es)
PT (1) PT776898E (es)
RU (1) RU2178415C2 (es)
SK (1) SK281807B6 (es)
TW (1) TW382629B (es)
ZA (1) ZA9610008B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399621B1 (en) 1999-08-10 2002-06-04 American Cyanamid Company N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US20030091632A1 (en) * 1999-08-26 2003-05-15 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US6384221B1 (en) * 1999-09-02 2002-05-07 Neurocrine Biosciences, Inc. Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
AU2001283119B2 (en) * 2000-08-03 2007-11-15 Wyeth Polymorphs of zaleplon and methods for the preparation thereof
EP1526136A1 (en) * 2000-08-03 2005-04-27 Wyeth Polymorphs of zaleplon and methods for the preparation thereof
AR029780A1 (es) 2000-12-13 2003-07-16 Gador Sa Procedimiento mejorado para la obtencion de n-[3(3-ciano-pirazolo[1,5-a]pirimidin-7-il)fenil]-n-etil-acetamida
PL372942A1 (en) * 2001-06-12 2005-08-08 Biogal Gyogyszergyar Rt Process for the production of n-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl)phenyl]-n-ethylacetamide (zaleplon)
US20050032818A1 (en) * 2001-06-12 2005-02-10 Entire Interest N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl]-N-ethylacetamide and crystalline forms of zaleplon
IL160076A0 (en) * 2001-08-01 2004-06-20 Biogal Gyogyszergyar Process for purifying n-[3-(3-cyanopyrazolo{1,5-a} pyrimidin-7-yl) phenyl]-n-ethylacetamide (zaleplon) and crystalline forms of zaleplon accessible with the process
EP1476446B1 (de) * 2002-02-14 2007-08-01 Cilag AG Verfahren zur herstellung von n-ethyl-n-(3-(3-cyanopyrazolo-(1,5-a)-pyrimidin-7-yl)phenyl)-acetamid
WO2003068238A1 (en) * 2002-02-15 2003-08-21 Biogal Gyogyszergyar Rt. Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom
PL207322B1 (pl) * 2002-05-14 2010-11-30 Adamed Społka Z Ograniczoną Odpowiedzialnością Sposób wytwarzania zaleplonu
KR101248123B1 (ko) 2003-09-04 2013-03-27 씨아이피엘에이 엘티디. 잘레플론의 합성
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
DE602004025747D1 (de) * 2004-01-14 2010-04-08 Mallinckrodt Inc Zweiphasiges verfahren zur synthese ausgewählter pyrazolopyrimidine
HUP0400325A3 (en) 2004-02-02 2005-11-28 Richter Gedeon Vegyeszet Pure n-[3-(-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethyl-acetamide, process for its preparation and intermediates
WO2005079851A2 (en) 2004-02-18 2005-09-01 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
WO2006070244A2 (en) * 2004-11-22 2006-07-06 Bakulesh Mafatlal Khamar A process for the preparation of zaleplon
TW200815428A (en) * 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
WO2008021337A1 (en) 2006-08-15 2008-02-21 Wyeth Oxazinan-2-one derivatives useful as pr modulators
US7649007B2 (en) * 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
WO2008021309A1 (en) * 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
WO2008068600A2 (en) * 2006-12-06 2008-06-12 Orchid Chemicals & Pharmaceuticals Limited An improved process for the preparation of zaleplo
CZ2008468A3 (cs) 2008-07-31 2009-11-18 Farmak, A. S. Zpusob prípravy N-(1-benzo[b]thien-2-ylethyl)-N-hydroxymocoviny
CN102816163A (zh) * 2012-08-20 2012-12-12 四川禾邦阳光制药股份有限公司 扎来普隆的新晶型及制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907799A (en) * 1971-08-16 1975-09-23 Icn Pharmaceuticals Xanthine oxidase inhibitors
US4281000A (en) * 1979-07-09 1981-07-28 American Cyanamid Company Substituted pyrazolo (1,5-a)pyrimidines and their use as anxiolytic agents
NZ208554A (en) * 1983-06-23 1987-06-30 American Cyanamid Co (aryl and heteroaryl)-(7-(aryl and heteroaryl)-pyrazolo (1,5-a) pyrimidin-3-yl)-methanone derivatives and pharmaceutical compositions
US4521422A (en) * 1983-06-23 1985-06-04 American Cyanamid Company Aryl and heteroaryl[7-(aryl and heteroaryl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones
US4626538A (en) * 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
JPS62270584A (ja) * 1986-04-28 1987-11-24 Yoshitomi Pharmaceut Ind Ltd ４，７−ジヒドロピラゾロ〔１，５−ａ〕ピリミジン誘導体
RO108347B1 (ro) * 1989-10-30 1994-04-28 Bellon Labor Sa Roger DERIVATI DE BENZO-(b)-NAFTIRIDIN-1,8 SI PROCEDEU DE PREPARARE A ACESTORA
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
GB9321162D0 (en) * 1993-10-13 1993-12-01 Boots Co Plc Therapeutic agents

Also Published As

Publication number Publication date
CN1163893A (zh) 1997-11-05
US5714607A (en) 1998-02-03
BR9605760A (pt) 1998-08-25
AU7409196A (en) 1997-06-05
PT776898E (pt) 2003-02-28
IL119710A0 (en) 1997-02-18
DE69624657D1 (de) 2002-12-12
MX9605974A (es) 1998-04-30
HUP9603275A3 (en) 1997-10-28
NO965084L (no) 1997-06-02
EP0776898B1 (en) 2002-11-06
DK0776898T3 (da) 2003-02-24
CZ292253B6 (cs) 2003-08-13
SK281807B6 (sk) 2001-08-06
AR004822A1 (es) 1999-03-10
DE69624657T2 (de) 2003-08-21
HU9603275D0 (en) 1997-01-28
CN1057525C (zh) 2000-10-18
IL119710A (en) 1999-11-30
NZ299848A (en) 1998-09-24
EP0776898A1 (en) 1997-06-04
ATE227290T1 (de) 2002-11-15
HUP9603275A2 (en) 1997-08-28
NO307181B1 (no) 2000-02-21
CZ350596A3 (en) 1997-09-17
KR970042543A (ko) 1997-07-24
ZA9610008B (en) 1998-08-28
KR100439282B1 (ko) 2004-08-31
JP4112032B2 (ja) 2008-07-02
JPH09216885A (ja) 1997-08-19
AU718310B2 (en) 2000-04-13
NO965084D0 (no) 1996-11-28
RU2178415C2 (ru) 2002-01-20
TW382629B (en) 2000-02-21
HU226398B1 (en) 2008-11-28
SK153696A3 (en) 1997-11-05
CA2191647A1 (en) 1997-06-02
CA2191647C (en) 2005-01-25
CY2440B1 (en) 2004-11-12

Similar Documents

Publication Publication Date Title
ES2184844T3 (es) Procedimiento mejorado de sintesis de n-(3-(3-cianopirazolo(1,5-a)pirimidin-7-il)fenil)n-etilacetasmida.
BR9906287A (pt) Bactéria pertencente ao gênero escherichia e que tem uma capacidade para produzir um l-aminoácido, e, processo para produzir um l-aminoácido
ZA9810444B (en) Use of 9-deoxy-2',9-methano-3-oxa-4,5,6-trinor-3,7-(1',3'interphenylene)-13,14-dihydroprostaglandin F1 to treat peripheral vascular disease
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
IL134142A0 (en) Catalytic monoclonal antibodies with protease activity for the selective lysis of the protein component of plaques and aggregates related to pathological conditions
BR9906903A (pt) Composição com liberação sustentada, processos para produzir a mesma, para suprimir a brusca liberação inicial da susbtância bioativa de uma composição com liberação sustentada e para aumentar a eficiência da inclusão da substância bioativa em uma composição com liberação sustentada, produto farmacêutico, agente para prevenir ou tratar câncer prostático, hipertrofia prostática, endometriose, histeromioma, metrofibroma, puberdade precoce, dismenorréia, ou câncer do seio, ou um contraceptivo, e, composto
IL177228A0 (en) Use of a vector for the manufacture of a medicament for treating gaucher disease
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
GR3023038T3 (en) Use of coconut precursor fatty acid as insect-repellent.
ES482414A1 (es) Procedimiento para la preparacion del acido 4-aminohex-5- anoico o una sal del mismo.
LT2000087A (lt) Dezinfekavimo kompozicija
SV1996000008A (es) Uso de amidas de acido fenilciclohexilcarboxilicos
HU9303227D0 (en) D-3 vitamine analogues and process for producing them
AR004093A1 (es) El uso de una proteina derivada de una quimioquina de mamifero y un medicamento util para movilizar celulas tronco hematopoyeticas.
ATE103166T1 (de) Haarbehandlungszusammensetzung.
TR199802601A2 (xx) Susuz Sodyum S�lf�r�n Haz�rlanma Y�ntemi
DK325387D0 (da) 4-benzyloxy-3-pyrrolin-2-on-1-yl-acetamid samt dets fremstilling og anvendelse
ES2159967T3 (es) Medicamento que contiene acido delta-aminolevulinico.
BR9911378A (pt) Processo para fabricar um pó antiperspirante.
BR8906421A (pt) Processo para preparacao de monopersulfato de piridina-3-acido peroxicarboxilico
EP0734255A4 (en) NEW POTASSIUM CHANNEL AGONIST RECEIVED BY TRICHODERMA VIRENS
BR0207953A (pt) Derivados de caloporosida, processos para a sua preparação e sua aplicação
ZA82393B (en) Base-substituted anthranilic acids,a process for their preparation and their use
BR9611805A (pt) Derivados de amino álcool processos para a sua produção e agentes farmacêuticos contendo estes compostos